Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken

Yoko Fujimoto, Director, Japan Disease Area Leader, Clinical Research, Pfizer Japan New drugs with potential to become radical treatments of Alzheimer’s disease (AD) have once again run into a wall in PIII clinical trials. Between early and late August, Pfizer...read more